Theratechnologies Inc. is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy. EGRIFTA is indicated for the treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference of approximately 100 centimeters for males and approximately 90 centimeters for females. Ibalizumab is a cluster difference 4 (CD4)-directed HIV entryinhibitor, which focuses on treating multidrug resistant HIV-1 infection (MDR HIV-1). ibalizumab binds to the second extracellular domain of the CD4 receptor. Ibalizumab has completed the Phase III trial. EGRIFTA is available in Canada and in the United States. The Company distributes EGRIFTA in the United States through RxC Acquisition Company.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: TSE:TH
- CUSIP: N/A
- Web: www.theratech.com
- Market Cap: C$547.69 million
- Outstanding Shares: 74,415,000
- 50 Day Moving Avg: C$7.77
- 200 Day Moving Avg: C$5.74
- 52 Week Range: C$2.35 - C$8.72
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: -198.68
- Annual Revenue: C$38.35 million
- Price / Sales: 14.28
- Book Value: C$0.61 per share
- Price / Book: 12.07
- EBIDTA: $737,999.00
- Net Margins: -24.83%
- Return on Equity: -26.95%
- Return on Assets: -14.73%
- Average Volume: 168,844 shs.
- Short Ratio: 1.85
Frequently Asked Questions for Theratechnologies (TSE:TH)
What is Theratechnologies' stock symbol?
Theratechnologies trades on the Tornton Stock Exchange (TSX) under the ticker symbol "TH."
How were Theratechnologies' earnings last quarter?
Theratechnologies Inc (TSE:TH) issued its earnings results on Tuesday, July, 14th. The company reported $0.01 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.02) by $0.03. The company earned $7.08 million during the quarter, compared to the consensus estimate of $6.45 million. Theratechnologies had a negative return on equity of 26.95% and a negative net margin of 24.83%. View Theratechnologies' Earnings History.
Where is Theratechnologies' stock going? Where will Theratechnologies' stock price be in 2017?
2 brokers have issued 12-month target prices for Theratechnologies' stock. Their predictions range from C$7.15 to C$9.50. On average, they anticipate Theratechnologies' share price to reach C$8.05 in the next twelve months. View Analyst Ratings for Theratechnologies.
Who are some of Theratechnologies' key competitors?
Some companies that are related to Theratechnologies include ProMetic Life Sciences (PLI), SunOpta (SOY), Lucara Diamond Corp (LUC), Spartan Energy Corp (SPE), Labrador Iron Ore Royalty Corporation (LIF), Altus Group Ltd (AIF), Ensign Energy Services (ESI), TMAC Resources (TMR), Western Forest Products (WEF), Torc Oil And Gas Ltd (TOG), MTY Food Group (MTY), Semafo (SMF), Fortuna Silver Mines (FVI), Just Energy Group (JE), Badger Daylighting Ltd (BAD), Chorus Aviation (CHR), Nevsun Resources (NSU) and Martinrea International (MRE).
Who are Theratechnologies' key executives?
Theratechnologies' management team includes the folowing people:
- Dawn Svoronos, Independent Chairman of the Board
- Luc Tanguay, President, Chief Executive Officer, Director
- Philippe Dubuc, Chief Financial Officer, Senior Vice President
- Lyne Fortin, Senior Vice President, Chief Commercial Officer
- Christian Marsolais Ph.D., Senior Vice President - Scientific Affairs and Alliances
- Marie-Noel Colussi, Vice President - Finance
- Jocelyn Lafond, Vice President - Legal Affairs, Corporate Secretary
- Pierre Perazzelli, Vice President - Pharmaceutical Development
- Dale Weil, Director
- Gilles Cloutier Ph.D., Independent Director
How do I buy Theratechnologies stock?
Shares of Theratechnologies and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Theratechnologies' stock price today?
MarketBeat Community Rating for Theratechnologies (TSE TH)MarketBeat's community ratings are surveys of what our community members think about Theratechnologies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Theratechnologies stock can currently be purchased for approximately C$7.36.
Consensus Ratings for Theratechnologies (TSE:TH) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating, 1 Buy Rating|
|Consensus Rating:||Buy (Score: 2.50)|
|Consensus Price Target: ||C$8.05|
Analysts' Ratings History for Theratechnologies (TSE:TH)
(Data available from 7/22/2015 forward)
|7/3/2017||National Bank Financial||Downgrade||Outperform Market Weight -> Sector Perform Market Weight|
|5/5/2017||Canaccord Genuity||Reiterated Rating||Speculative Buy||C$7.50|
|7/6/2016||Mackie||Lower Price Target||C$5.30 -> C$4.40|
Earnings History for Theratechnologies (TSE:TH)Earnings History by Quarter for Theratechnologies (TSE TH)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|7/14/2015||Q2||($0.02)||$0.01||$6.45 million||$7.08 million||View||Listen|
Earnings Estimates for Theratechnologies (TSE:TH)
Current Year EPS Consensus Estimate: $-0.17 EPS
Dividend History for Theratechnologies (TSE:TH)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Theratechnologies (TSE:TH)Insider Trades by Quarter for Theratechnologies (TSE:TH)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|7/7/2016||G�Rald A Lacoste||Director||Buy||4,000||C$2.36||C$9,440.00|
|6/26/2015||G�Rald A Lacoste||Director||Buy||10,000||C$1.47||C$14,700.00|
Headline Trends for Theratechnologies (TSE:TH)
Latest Headlines for Theratechnologies (TSE:TH)
Theratechnologies (TH) Chart for Saturday, July, 22, 2017